VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Saccharomyces boulardi (Sb)
Phase 3
Small molecule
F
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Diarrhea
1 trial
Effect of Saccharomyces Boulardii CNCM I-745 (Sb) on Bloody Diarrhea in Children. A Double Blind, Randomized, Controlled Study ( Sb192-SUH )
Active, not recruiting
·
F
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan
·
Phase 4
·
NCT07371819
·
140 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Saccharomyces boulardi (Sb). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Saccharomyces boulardi (Sb) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Saccharomyces boulardi (Sb). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
F
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan
Related News